Trial Profile
Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Fulvestrant; Goserelin; Palbociclib
- Indications Advanced breast cancer; Bone metastases; Cancer metastases; Early breast cancer; HER2 negative breast cancer; Liver metastases
- Focus Adverse reactions; Registrational
- 25 Jan 2022 Planned End Date changed from 1 Sep 2020 to 15 Mar 2022.
- 25 Jan 2022 Planned primary completion date changed from 1 Sep 2020 to 15 Feb 2022.
- 25 Jan 2022 Status changed from recruiting to active, no longer recruiting.